| Bruker Corporation Q1 2010 Earnings Call Transcript Bruker Corporation (BRKR)Q1 2010 Earnings Conference CallApril 29, 2010 9:00 AM ETComplete Story » seekingalpha.com |
J&J Buys Into Diabetes Drug Johnson & Johnson will pay $45 million up front and could pay more than $625 million in total to develop a type-1 diabetes drug created by Sweden's Diamyd Medical. online.wsj.com |
Hedge Fund Bridger Management Ups XenoPort Stake Market Folly submits:Roberto Mignone's hedge fund Bridger Management filed a 13G with the SEC after market close today regarding shares of XenoPort (XNPT). Due to portfolio activity on July 7th, Bridger has disclosed a 6.6% ownership stake in XNPT with 2,000,000 shares. This marks a 42.8% increase in Bridger's position size as the hedge fund previously owned 1,400,000 shares back on March 31st, 2010. In past coverage, we've seen a divergence of opinion regarding XenoPort amongst hedge funds. Back in May of this year, Steve Cohen's hedge fund SAC Capital showed a XNPT stake while Lee Ainslie's Maverick Capital sold out of the name back in the first quarter. Shares of XenoPort have recently sold off hard from $9 per share down to now around $6.Complete Story » seekingalpha.com |
Appeals Court Upholds Pay-to-Delay Deals, Again Pharmalot submits: In yet another blow to the US Federal Trade Commission, a federal appeals court has refused to reconsider its ruling last April that upheld the legality of so-called pay-for-delay deals that thwart the introduction of generic rivals (here is the order). However, in a dissenting opinion, Justice Rosemary Pooler writes that the issue must ultimately be decided by the US Supreme Court, given the conflicting outcomes in various cases. The initial ruling by the US Second Circuit Court of Appeals was made after reviewing a deal in which Bayer (BAYRY.PK) paid Barr Pharmaceuticals (BRL), which is now owned by Teva Pharmaceuticals (TEVA), to drop its patent challenge to the Cipro antibiotic. Barr challenged the Cipro patent in October 1991 and struck a deal with Bayer in January 1997, about two weeks before the case was set to go to trial.Complete Story » seekingalpha.com |
Dendreon Stays in Neutral Zacks.com submits: We are maintaining our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $44.00. Dendreon, founded in 1992 and headquartered in Seattle, Washington, is a biotechnology company focused on developing drugs for cancer. The company received a huge boost with the US Food and Drug Administration (FDA) approving Provenge (sipuleucel-T), a therapeutic vaccine for treating advanced prostate cancer in men.Complete Story » seekingalpha.com |